Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-11 EDT			5-day change	1st Jan Change
4.140 ^USD	-5.91%		-13.03%	-42.58%

07-09	Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease	CI
06-30	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index	CI

Stifel Initiates Altimmune at Buy With $18 Price Target

Published on 2025-01-08 at 09:07, updated on 2025-01-08 at 09:08

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Altimmune, Inc.

Altimmune, Inc. Announces Initiation of Restore Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease	07-09	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2500 Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2000 Value Index	06-30	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Microcap Value Index	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000E Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2500 Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2000 Value Benchmark	06-29	CI
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Microcap Value Benchmark Index	06-29	CI
Altimmune, Inc. - Special Call	06-26
Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints	06-26	RE
Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution	06-26	MT
Altimmune's weight-loss drug meets main goal in fatty liver disease trial	06-26	RE
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH	06-25	CI
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	06-18	RE
Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025	05-23
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	05-19	RE
Altimmune, Inc. Announces Initiation of RECLAIM Phase 2 Trial Evaluating Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	05-19	CI
Weight-loss drug developers line up to tap lucrative market as competition heats up	05-16	RE
Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital	05-13	MT
Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital	05-13	RE

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-06 - Q2 2025 Earnings Release (Projected)

More about the company